

The Interferons

Characterization and Application

Edited by Anthony Meager



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

The Interferons

*Edited by
Anthony Meager*

Related Titles

Frosch, M., Maiden, M. C. J. (eds.)

Handbook of Meningococcal Disease

Infection Biology, Vaccination, Clinical Management

approx. 600 pages with approx. 90 figures

Hardcover

ISBN 3-527-31260-9

Kaufmann, S. H. E. (ed.)

Novel Vaccination Strategies

670 pages with 82 figures and 50 tables

2004

Hardcover

ISBN 3-527-30523-8

Lutz, M. B., Romani, N., Steinkasserer, A. (eds.)

Handbook of Dendritic Cells

Biology, Diseases, and Therapies

approx. 1250 pages in 3 volumes

Hardcover

ISBN 3-527-31109-2

Kalden, J. R., Herrmann, M. (eds.)

Apoptosis and Autoimmunity

From Mechanisms to Treatments

392 pages with 50 figures and 25 tables

2003

Hardcover

ISBN 3-527-30442-8

Pollard, K. M. (ed.)

Autoantibodies and Autoimmunity

Molecular Mechanisms in Health and Disease

approx. 700 pages

2005

Hardcover

ISBN 3-527-31141-6

Stuhler, G., Walden, P. (eds.)

Cancer Immune Therapy

Current and Future Strategies

434 pages with 57 figures and 29 tables

2002

Hardcover

ISBN 3-527-30441-X

Kropshofer, H., Vogt, A. B. (eds.)

Antigen Presenting Cells

From Mechanisms to Drug Development

651 pages with 63 figures and 16 tables

2005

Hardcover

ISBN 3-527-31108-4

The Interferons

Characterization and Application

Edited by Anthony Meager



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

The Editor

Dr. Anthony Meager

National Institute for Biological
Standards and Control
Division of Immunology and
Endocrinology

- All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for
British Library Cataloguing-in-Publication Data:
A catalogue record for this book is available
from the British Library.

**Bibliographic information published by
Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in
the Deutsche Nationalbibliografie; detailed
bibliographic data is available in the Internet at
<<http://dnb.ddb.de>>.

© 2006 WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim

All rights reserved (including those of
translation into other languages). No part of
this book may be reproduced in any form – by
photoprinting, microfilm, or any other means –
nor transmitted or translated into a machine
language without written permission from the
publishers. Registered names, trademarks, etc.
used in this book, even when not specifically
marked as such, are not to be considered
unprotected by law.

Printed in the Federal Republic of Germany.
Printed on acid-free paper.

Typesetting Asco Typesetters, Hong Kong
Printing betz-Drude GmbH, Darmstadt
Binding Litges & Dopf Buchbinderei GmbH,
Heppenheim

ISBN-13: 978-3-527-31180-4

ISBN-10: 3-527-31180-7

Contents

Preface XIII

List of Contributors XV

Color Plates XIX

Section A Molecular Aspects, Introduction and Purification 1

1	Type I Interferons: Genetics and Structure	3
	<i>Shamith A. Samarajiwa, William Wilson and Paul J. Hertzog</i>	
1.1	Introduction	3
1.2	The Type I IFN Genetic Locus	4
1.3	Type I IFN Genes	7
1.3.1	IFN- α	7
1.3.2	IFN- β	7
1.3.3	IFN- ω	8
1.3.4	IFN- κ	8
1.3.5	IFN- ϵ	9
1.3.6	IFN- ζ (Limitin)	9
1.3.7	IFN- τ	9
1.3.8	IFN- δ	10
1.3.9	IFN- ν	10
1.4	Type I IFN Gene-regulatory Regions	11
1.5	Evolution of the Type I IFNs	15
1.5.1	Vertebrate IFN Genes	15
1.5.2	The Expansion and Divergence of the IFN Genes	20
1.6	Natural and Induced Mutations in IFN Genes	21
1.7	Secondary Structural Features of Type I IFNs	22
1.7.1	Conserved Amino Acid Residues	22
1.7.2	Post-translational Modifications of Type I IFNs	23
1.7.3	Conserved Cysteine Residues and Disulfide Bond Formation	24
1.8	The Structure of Type I IFNs	24
	References	27

2	Activation of Interferon Gene Expression Through Toll-like Receptor-dependent and -independent Pathways	35
	<i>Peyman Nakhaei, Suzanne Paz and John Hiscott</i>	
2.1	Introduction	35
2.2	IFN- β Gene Transcription	39
2.3	IRF Family Members	40
2.4	Role of IRFs in Virus-mediated IFN Activation	41
2.4.1	IRF-3	41
2.4.2	IRF-5	47
2.4.3	IRF-7	48
2.5	IFN Signaling Pathways	49
2.5.1	TLR-dependent Signaling to IFN Activation	49
2.5.1.1	TLR Overview	49
2.5.1.2	TLR-3 Signaling	51
2.5.1.3	TLR-4 Signaling	53
2.5.1.4	TLR-7 Signaling	57
2.5.1.5	TLR-9 Signaling	57
2.5.2	TLR-independent Signaling	58
2.5.2.1	Retinoic-inducible Gene (RIG)-I Signaling	58
2.5.2.2	Melanoma Differentiation-associated Gene-5 (<i>mda-5</i>)	59
2.6	Conclusions	61
	References	61
3	Interferon Proteins: Structure, Production and Purification	73
	<i>Dimitris Platis and Graham R. Foster</i>	
3.1	Introduction	73
3.2	The Structure of Type I IFNs	73
3.3	Production and Purification of Type I IFNs	75
3.3.1	Leukocyte-derived IFN – First Steps in Producing Commercial IFN	75
3.3.2	Lymphoblastoid IFN – Towards more Reliable Supplies of IFN	76
3.3.3	Cloned Type I IFNs – An Inexhaustible Supply of Therapeutic Material	76
3.4	Long-acting IFNs	78
3.5	Summary	79
	References	80
4	Interferon-γ: Gene and Protein Structure, Transcription Regulation, and Actions	85
	<i>Ana M. Gamero, Deborah L. Hodge, David M. Reynolds, Maria Cecilia Rodriguez-Galan, Mansour Mohamadzadeh and Howard A. Young</i>	
4.1	Introduction	85
4.2	IFN- γ Gene Structure and Regulation	86
4.2.1	Transcriptional Regulation	86
4.2.2	Epigenetic Regulation	88
4.2.3	Post-transcriptional Regulation	90

4.3	IFN- γ Signal Transduction	90
4.3.1	The JAK-STAT Signaling Pathway	91
4.3.2	Activation of Alternate Signaling Pathways	92
4.3.3	Regulation of IFN- γ Signaling	93
4.4	IFN- γ in T _h Cell Development	95
4.4.1	Signaling Pathways Involved in T Cell Development	95
4.5	IFN- γ and DCs	97
4.5.1	IFN- γ and T Cell-DC Crosstalk	97
4.5.2	Signals through Toll-like Receptors (TLRs) Activate DCs and Influence IFN- γ Expression	99
4.6	IFN- γ – Role in Tumor Development and Growth	100
4.6.1	IFN- γ in Tumor Growth and Survival	100
4.6.2	Inhibition of Angiogenesis by IFN- γ	101
4.6.3	Role of IFN- γ in Promoting Immune Responses against Tumors	102
4.7	Summary	103
	References	104
5	Interferon and Related Receptors	113
	<i>Sidney Pestka and Christopher D. Krause</i>	
5.1	Introduction	113
5.2	IFNs and IFN-like Molecules in Brief	113
5.3	The Receptors	114
5.3.1	Receptor Nomenclature	115
5.4	The Type I IFN Receptor	116
5.4.1	Discovery of the Type I Receptor Complex	117
5.4.2	Diversity of the Interaction of Type I IFNs with the Receptor	119
5.5	The Type II IFN (IFN- γ) Receptor	121
5.5.1	Chromosomal Localization of the IFN- γ Receptor Ligand-binding Chain and Discovery of Two Chains Required for Activity	121
5.5.2	The IFN- γ R1 Chain	123
5.5.3	The Second Receptor Chain (IFN- γ R2)	123
5.5.4	The Functional IFN- γ R Complex	124
5.5.4.1	Specificity of Ligand Binding	124
5.5.4.2	Specificity of the Interactions of the Two Chains	124
5.5.5	Specificity of Signal Transduction	124
5.5.6	Receptor Structure	125
5.5.7	Preassembly of the Receptor Complex	126
5.6	The IL-28R1 and -10R2 Receptor Complex	127
5.7	Overview of Multichain Receptors	128
5.8	Global Summary	128
	References	129
6	Type III Interferons: The Interferon-λ Family	141
	<i>Sergei V. Kotenko and Raymond P. Donnelly</i>	
6.1	Introduction	141

6.2	The Class II Cytokine Receptor Family (CRF2) and their Ligands	142
6.3	Genomic Structure	145
6.4	Receptor Complex and Signaling	148
6.5	Biological Activities	152
6.6	The Murine IFN- λ Antiviral System	154
6.7	Evolution of the IFN Family	156
6.8	Therapeutic Potential	157
6.9	Conclusions	158
	References	158

Section B Biological Properties 165

7	Biological Actions of Type I Interferons	167
	<i>Melissa M. Brierley, Jyothi Kumaran and Eleanor N. Fish</i>	
7.1	Introduction	167
7.2	Sources of Type I IFN Production and Secretion	167
7.3	Type I IFN Interactions with the Receptor Complex	168
7.3.1	Structure and Functional Regions of Type I IFNs	168
7.3.2	IFN Domains Mediating Interactions with IFNAR-2	168
7.3.3	IFNAR-2 Domains Mediating Interactions with IFNs	170
7.3.4	IFN- α Interaction with IFNAR-2	172
7.3.5	IFN- β Interaction with IFNAR-2	173
7.3.6	Type I IFN Interactions with IFNAR-1	174
7.3.7	IFNAR-1 Receptor Interaction with Glycosphingolipids	174
7.3.8	Residues in Type I IFNs that Mediate Biological Responses	175
7.4	Type I IFN-induced Signaling Cascades	175
7.4.1	The JAK–STAT (Signal Transducers and Activators of Transcription) Pathway	175
7.4.1.1	The Importance of STAT-1 and -2 in Type I IFN Signaling	178
7.4.2	Other IFN-inducible Signaling Cascades	179
7.4.2.1	The CrkL Pathway	179
7.4.2.2	The IRS Pathway	179
7.4.2.3	The p38 Mitogen-activated Protein Kinases (MAPK) Pathway	181
7.4.2.4	The Vav Protooncogene and IFN Signaling	182
7.4.2.5	The Protein Kinase C (PKC) Family and IFN Signaling	182
7.5	IFN-inducible Biological Responses	183
7.5.1	IFN-inducible Antiviral Responses	183
7.5.1.1	PKR	186
7.5.1.2	2'–5'-OAS/RNase L	186
7.5.1.3	Mx	187
7.5.1.4	Other IFN-inducible Antiviral Effectors	188
7.5.2	IFN-inducible Growth-inhibitory Responses	188
7.5.3	IFN-inducible Immunomodulation	190
7.6	Summary	192
	References	193

8	Interferons and Apoptosis – Recent Developments	207
	<i>Michael J. Clemens and Ian W. Jeffrey</i>	
8.1	Introduction	207
8.2	The Role of IFN-regulated Genes in the Control of Apoptosis	209
8.2.1	Proapoptotic Genes Induced by IFNs	209
8.2.2	p53 and IFN-induced Apoptosis	209
8.2.3	The Ribonuclease (RNase) L System	210
8.3	The Protein Kinase PKR and the Phosphorylation of Polypeptide Chain Initiation Factor eIF2 α	212
8.3.1	Regulation of Apoptosis by PKR	212
8.3.2	The Role of eIF2 α Phosphorylation	212
8.4	IFNs and the Apoptotic Effects of TRAIL	215
8.4.1	TRAIL Induction	215
8.4.2	TRAIL Activity	215
8.5	Signal Transduction Pathways for IFN-mediated Effects on Apoptosis	218
8.6	The Antiapoptotic Effects of IFNs	219
8.7	Conclusions	220
	Acknowledgments	220
	References	221
9	Viral Defense Mechanisms against Interferon	227
	<i>Santanu Bose and Amiya K. Banerjee</i>	
9.1	Introduction	227
9.2	Innate Immune Antiviral Defense Mechanisms of Host Cells	227
9.3	Evasion of IFN-mediated Antiviral Response	231
9.3.1	Nonsegmented Negative-strand RNA Viruses	232
9.3.1.1	Paramyxoviruses	232
9.3.1.2	Filovirus	242
9.3.1.3	Rhabdovirus	242
9.3.2	Segmented Negative-strand RNA Viruses	242
9.3.2.1	Orthomyxovirus	243
9.3.2.2	Bunyaviruses	243
9.3.3	Positive-sense ssRNA Viruses	244
9.3.3.1	Picornaviruses	244
9.3.3.2	Flaviviruses	244
9.3.3.3	Coronavirus	246
9.3.4	dsRNA Viruses	247
9.3.5	RNA and DNA Reverse-transcribing Viruses	247
9.3.5.1	Retrovirus	247
9.3.5.2	Hepadnavirus	248
9.3.6	dsDNA Viruses	248
9.3.6.1	Adenovirus	248
9.3.6.2	Poxvirus	248
9.3.6.3	Herpesvirus	250

9.3.6.4	Papillomavirus	252
9.4	Concluding Remarks	253
	References	254

Section C Clinical Applications 275

10	Overview of Clinical Applications of Type I Interferons	277
	<i>Frank Müller</i>	
10.1	Introduction	277
10.2	Biological Effects	277
10.3	Type I IFN Products Currently Available or Under Development	278
10.4	Pharmacokinetics	284
10.4.1	IFN- α	284
10.4.2	IFN- β	285
10.5	Clinical Applications of Type I Interferons	285
10.5.1	Chronic hepatitis B (CHB)	286
10.5.2	Chronic hepatitis C (CHC)	288
10.5.3	Chronic hepatitis D (CHD)	290
10.5.4	Hairy Cell Leukemia (HCL)	290
10.5.5	Renal Cell Carcinoma (RCC)	291
10.5.6	Basal Cell Carcinoma (BCC)	292
10.5.7	Malignant Melanoma	292
10.5.8	Kaposi Sarcoma (KS)	292
10.5.9	Multiple Myeloma	293
10.5.10	Chronic myelogenous leukemia (CML)	294
10.5.11	Non-Hodgkinis lymphoma (NHL)	295
10.5.12	Laryngeal Papillomatosis	295
10.5.13	Mycosis Fungoides (MF)	296
10.5.14	Condyloma Acuminata	296
10.5.15	Multiple Sclerosis (MS)	297
10.6	IFN Toxicity	298
10.7	Type I IFNs in the Future	299
	References	300
11	Clinical Applications of Interferon-γ	309
	<i>Christine W. Czarniecki and Gerald Sonnenfeld</i>	
11.1	Introduction	309
11.2	IFN- γ – The Molecule	311
11.3	FDA-approved Indications: Established Benefit and Risks	311
11.3.1	Chronic Granulomatous Disease (CGD)	311
11.3.2	Osteopetrosis	313
11.3.3	Adverse Reactions	314
11.4	Infectious Diseases	314
11.4.1	Mycobacterial Infection	314
11.4.1.1	Leprosy	314

11.4.1.2	<i>Mycobacterium avium</i> Infection	315
11.4.1.3	Tuberculosis (TB)	315
11.4.2	Leishmaniasis	317
11.4.3	Opportunistic Infections in HIV Disease	317
11.5	Infection Following Serious Trauma	318
11.6	Atopic Dermatitis (AD)	321
11.7	Idiopathic Pulmonary Fibrosis (IPF)	322
11.8	Systemic Sclerosis (SSc)	326
11.9	Radiation-induced Fibrosis	326
11.10	Chronic Hepatitis	327
11.11	Oncology Indications: Ovarian Cancer	329
11.12	Conclusions	330
	References	331

Section D Measurement of Interferons and Anti-Interferons 337

12	Measurement of Interferon Activities	339
	<i>Tony Meager</i>	
12.1	Introduction	339
12.2	The IFNs: Mechanisms of Action, Protein Induction and Biological Activities	340
12.2.1	Mechanisms of Action	340
12.2.2	Protein Induction	342
12.2.3	Biological Activities	344
12.2.3.1	Antiviral Activity	344
12.2.3.2	Antiproliferative Activity	344
12.2.3.3	Immunomodulatory Activity	345
12.3	Measurement of Biological Activities of IFNs	345
12.3.1	General Considerations	345
12.3.2	Biological Standards for IFNs	346
12.3.3	Practical Considerations for IFN Preparations	348
12.3.4	Antiviral Assays	349
12.3.5	Antiproliferative Assays	351
12.3.6	IFN-inducible Protein Assays	354
12.3.6.1	Bioimmunoassays	354
12.3.6.2	Enzyme Expression and Reporter Gene Assays	356
12.3.7	Assays Based on Intracellular Signaling Intermediates	361
12.3.8	Assay Design and Data Analysis	363
12.4	Regulatory Landscape	365
	Acknowledgments	366
	References	366

13	The Development and Measurement of Antibodies to Interferon	375
	<i>Sidney E. Grossberg and Yoshimi Kawade</i>	
13.1	Introductory Perspective	375
13.1.1	Immunological Perspective	375
13.1.2	Antibodies to Self-antigens	376
13.2	NAbs	377
13.2.1	Neutralization Bioassay Design	378
13.2.1.1	The Constant IFN Method	379
13.2.1.2	The Constant Antibody Method	380
13.2.2	Theoretical Analyses	382
13.2.3	Experimental Analyses	383
13.2.4	Standardization and the Reporting of Neutralization Results	383
13.2.5	A Solution to the Problem of NAb Unitage	385
13.3	Immunoassays for Non-NAbs	387
13.4	Epitope Analysis	388
13.5	Development of Antibodies during IFN Therapy	390
13.5.1	Antibodies to IFN- α	391
13.5.2	Antibodies to IFN- β	392
13.6	Summary	394
	References	395
	Index	401

Preface

The Interferon field has its origins nearly 50 years ago with the discovery of an antiviral factor produced by virally infected chick cells. This factor, designated “The Interferon”, provided the first evidence that antiviral defence mechanisms could be triggered by secreted cellular factors. Since interferon (IFN) was found to protect against many viruses, scientific interest was high. A research dynasty was literally founded then that has actively pursued the characterization and potential clinical applications of IFN. Initially, the field was sustained by dedicated pioneering scientists trying to understand what IFN was and how it worked. At the moment when their research was beginning to pay off with the purification of IFNs to homogeneity and increasing knowledge of their biological activities, the field was catalysed by the advent of recombinant DNA technology. The Pharmaceutical Industry too was drawn in by the “promise” of IFN’s broad therapeutic activity against a range of tumours and viruses. Although the clinical success of IFNs proved to be much more limited than hoped for, the research that was generated in those heady times gave a tremendous boost to our understanding of the molecular structure of IFN’ genes and proteins, their cellular receptors, their mechanism of action and their biological activities, both *in vitro* and *in vivo*. Despite the sombre assessment of the clinical worth of IFNs two decades ago, they have come back as strong market leaders for the treatment of chronic hepatitis C virus infection (IFN-alpha) and multiple sclerosis (IFN-beta). Research studies within the IFN field from then on have proved invaluable to the elucidation of IFN’ induction and connected intracellular signalling pathways, cellular defence mechanisms, and the evasion mechanisms of viruses and tumour cells to IFNs.

The Interferons: Characterization and Application covers many aspects of our current knowledge of IFNs. This includes the structure and functions of all known IFN types, evolution and structure of their genes, their receptors and signalling pathways, their induction and biological activities and mechanisms whereby viruses evade their antiviral actions. In addition, coverage of the clinical applications of type I and II IFNs, together with methodologies to measure biological activities of IFNs and the antibodies that may develop against them as a consequence of IFN therapies, is provided. I believe there is a serious need for this publication, even in view of the vast amount of information available in the scientific literature and on the World Wide Web. I feel that there is no substitute to an up-to-date monograph

on the IFN field that embraces an integrated and well-selected approach to the subject. It is my hope this will provide a comprehensive foundation to the professional scientific and medicinal research community, especially newcomers to the field, and will promote further advances in the field.

I gratefully acknowledge the authors for their time, motivation and dedication in preparing their contributions, without which this book would not have been possible. I also thank Andreas Sendtko and his colleagues at Wiley-VCH for outstanding support throughout the planning and preparation of this book.

Potters Bar, October 2005

Anthony Meager

ISAACS A, LINDEMANN J. Virus interference. I. The interferon.
Proc Roy Soc B 1957, 147, 258–267.

List of Contributors

Melissa M. Brierley

Toronto General Research Institute
University Health Network
Toronto, Ontario M5G 2M1
Canada

Amiya K. Banerjee

Virology Section
Department of Molecular Genetics
Lerner Research Institute
The Cleveland Clinic Foundation
Cleveland, OH 44195
USA

Santanu Bose

Department of Microbiology and Immunology
University of Texas Health Science Center at
San Antonio
San Antonio, TX 78229
USA

Michael J. Clemens

Translational Control Group
Department of Basic Medical Sciences
St George's Hospital Medical School
London SW17 0RE
UK

Christine W. Czarniecki

Division of Allergy, Immunology and
Transplantation
National Institute of Allergy and Infectious
Disease
National Institutes of Health
Bethesda, MD 20817
USA

Raymond P. Donnelly

Division of Therapeutic Proteins
Center for Biologics Evaluation and Research
Food and Drug Administration
Bethesda, MD 20892
USA

Eleanor N. Fish

Toronto General Research Institute
University Health Network
Toronto, Ontario M5G 2M1
Canada

Graham. R. Foster

Hepatobiliary Group
Institute of Cellular and Molecular Science
Queen Mary's School of Medicine and
Dentistry
Barts and The London
London E1 2AT
UK

Ana M. Gamero

Laboratory of Experimental Immunology
Center for Cancer Research
National Cancer Institute – Frederick
PO Box B, Bldg. 560, Rm. 31-18
Frederick, MD 21702-1201
USA

Sidney E. Grossberg

Department of Microbiology and Molecular
Genetics
Medical College of Wisconsin
Milwaukee, WI 53226
USA

John Hiscott

Terry Fox Molecular Oncology Group
Lady Davis Institute for Medical Research
Departments of Microbiology & Immunology
and Medicine
McGill University
Montreal, Quebec H3T 1E2
Canada

Paul J. Hertzog

Center for Functional Genomics and Human Disease
Monash Institute of Medical Research
Monash University
Clayton, Victoria 3168
Australia

Deborah L. Hodge

Laboratory of Experimental Immunology
Center for Cancer Research
National Cancer Institute – Frederick
PO Box B, Bldg. 560, Rm. 31-18
Frederick, MD 21702-1201
USA

Ian W. Jeffrey

Translational Control Group
Department of Basic Medical Sciences
St George's Hospital Medical School
London SW17 0RE
UK

Yoshimi Kawade

Kyoto University
Kyoto 43-6 Ozasaki-Minamigosho-cho,
Sakyo-ku Kyoto 606-8334
Japan

Jyothi Kumaran

Toronto General Research Institute
University Health Network
Toronto, Ontario M5G 2M1
Canada

Sergei V. Kotenko

Department of Biochemistry and Molecular Biology
University of Medicine and Dentistry
New Jersey Medical School
Newark, NJ 07103
USA

Christopher D. Krause

University of Medicine and Dentistry
Department of Molecular Genetics,
Microbiology and Immunology
Robert Wood Johnson Medical School
675 Hoes Lane, Room 801
Piscataway, NJ 08854-5635
USA

Tony Meager

Division of Immunology and Endocrinology
The National Institute for Biological Standards
and Control
South Mimms EN6 3QG
UK

Mansour Mohamadzadeh

Senior Investigator
USAMARIID
1425 Porter Street
Frederick, MD 21702
USA

Frank Müller

Rhein Minaphasm Biogenetics
El Bardissi Street
2T Taksseem Asmaa Fahmy
Heliopolis, Cairo
10th of Ramadan City

Peyman Nakhaei

Terry Fox Molecular Oncology Group
Lady Davis Institute for Medical Research
Departments of Microbiology & Immunology
McGill University
Montreal, Quebec H3T 1E2
Canada

Suzanne Paz

Terry Fox Molecular Oncology Group
Lady Davis Institute for Medical Research
Departments of Microbiology & Immunology
McGill University
Montreal, Quebec H3T 1E2
Canada

Sidney Pestka, M.D.

University of Medicine and Dentistry
Department of Molecular Genetics,
Microbiology and Immunology
Robert Wood Johnson Medical School
Chairman and Professor
G75 Hoes Lane, Room 727
Piscataway, NJ 08854-5635
USA

Sidney Pestka, M.D.

PBL Biomedical Laboratories
Chief Scientific Officer
131 Ethel Road West, Suite 6
Piscataway, NJ 08854-5900
USA

Dimitris Platis

Agricultural University of Athens
Department of Biotechnology
Laboratory of Enzyme Technology
118 55 Athens
Greece

David M. Reynolds

Laboratory of Experimental Immunology
Center for Cancer Research
National Cancer Institute – Frederick
PO Box B, Bldg. 560, Rm. 31-18
Frederick, MD 21702-1201
USA

Maria Cecilia Rodriguez-Galan

National University of Cordoba
Faculty of Chemistry
Hayas de la Torre y Medina Allende,
Ciudad Universitaria
CP (5000)
Ciudad de Cordoba, Cordoba
Argentina

Shamith A. Samarajiwa

Center for Functional Genomics and Human
Disease
Monash Institute of Medical Research
Monash University
Clayton, Victoria 3168
Australia

Gerald Sonnenfeld

Binghamton University
State University of New York
Binghamton, NY 13902
USA

Howard A. Young

Laboratory of Experimental Immunology
Center for Cancer Research – Frederick
National Cancer Institute
PO Box B, Bldg. 560, Rm. 31-23
Frederick, MD 21702-1201
USA

William Wilson

CSIRO Mathematical and Information
Sciences
Bioinformatics for Human Health
Clayton, Victoria 3168
Australia

Color Plates




Fig. 1.1. The human and murine type I IFN gene locus. (A) Human IFN gene cluster on chromosome 9 (HSA9). (B) Murine IFN gene cluster on chromosome 4 (MMU4). The IFN gene locus was drawn using current genomic information available on NCBI human chromosome 9 (HSA9) contig (contig ID; NT_008413.16) and mouse chromosome 4 (MMU) contig (contig ID; NT_039260.4). Arrows indicate relative position and transcriptional orientation of genes. Black arrows indicate functional IFN genes, dark grey arrows pseudogenes and light grey arrows other non-IFN genes within the cluster. Orientation of the chromosome is indicated by TEL (telomeric end) and CEN (centromeric end). Nomenclature suggested by van Pesch et al. [32] is used in naming murine IFNs. (This figure also appears on page 5.)




Fig. 1.2. Human type I IFN promoter sequence alignment. (A) VISTA alignment of human, mouse, rat, dog and cow IFN- β genes. The figure represents an AVID genome alignment [58] and VISTA visualization [59] of mouse, rat, dog and cow *ifnb* genomic sequences compared to the human *IFNβ* genomic sequence. At the top, the human *IFNβ* gene is depicted by a dark blue line with an arrow indicating transcriptional orientation, together with 5'- and 3'-UTR regions depicted as light blue lines. The line immediately below indicates the location of repetitive elements within the genomic sequence. The graphed regions below demonstrate homology of mouse, rat, dog and cow *ifnb* genomic regions to the human *IFNβ* gene. Exon regions with more than 65% sequence identity over 100 bp are indicated by dark blue, whereas conserved noncoding sequences (CNS) and 5'- and 3'-UTRs with over 65% sequence identity are depicted in orange and light blue, respectively. (This figure also appears on page 12.)

(B)




Fig. 1.2. (B) Nucleotide sequence alignment of human IFN promoter. Alignment was performed using ClustalW algorithm [79] of 500 bp 5'-flanking sequences containing the

promoter elements of human IFN genes. The regulatory elements present in this region are indicated by boxed regions. (This figure also appears on pages 14–15.)




Fig. 1.2B. (continued)





Fig. 1.4. Representative tertiary structure of human IFN- α . Tertiary structure of human IFN- α 2 represented as a ribbon diagram, showing the five α -helices connected by loop regions.

The disulfide bonds between cysteine residues are indicated by arrows. (A) Side view of the molecule. (B) View from above. (This figure also appears on page 25.)

Fig. 2.1. Schematic representation of the IFN- β promoter enhanceosome. This diagram shows the composition and organization of the human IFN- β enhanceosome. The nucleotide sequence (–110 to –36) is situated upstream from the starting transcription site. The positive regulatory sites as well as the negative regulatory domain are named PRDs and NRD, respectively. The transcriptional proteins binding to the PRDs are also shown (c-Jun, ATF-2, IRFs and NF- κ B), as well as the

architectural proteins HMGI(Y) and the transcriptional coactivators proteins p300 and CBP. The multiple protein–protein interactions required for transcriptional synergy of the IFN- β promoter derived from the cooperative assembly of the enhanceosome, cooperative assembly between the enhanceosome and the USA/BAD complex, and interaction with the RNA polymerase II complex [32]. (This figure also appears on page 38.)









Name	Structure	Size (aa)	Location
IRF-1		325	5q31.1
IRF-2		349	4q35.1
IRF-4		450	6p25-p23
IRF-6		467	1q32.2-q41
IRF-8 (ICSBP)		424	16q24.1
IRF-9 (ISG3γ/p48)		393	14q11.2

Fig. 2.2. Schematic representation of IRF-1, -2, -4, -6, -8 and -9 transcription factors. This diagram demonstrates the general structural homology amongst the IRF family. Different domains are shown: DBD, CKII phosphorylation site, repressor site and IAD. The size of each IRF as well as their chromosomal location is also described. (This figure also appears on page 44.)




Fig. 2.3. Schematic representation of IRF-3, -5 and -7 transcription factors. Different domains are shown: NLS, NES, DBD, CAD, VAD, IAD and the signal response domain (RD). The sequence of amino acids 382–414 (IRF-3) and

the sequence of amino acids 468–491 (IRF-7) are amplified below the schematic. Important amino acids are shown in larger letters with the respective position number. (This figure also appears on page 48.)

